Di.Bi.M.I.S, Internal Medicine Unit, "Villa Sofia-Cervello" Hospital, University of Palermo, Palermo, Italy,
Di.Bi.M.I.S, Internal Medicine Unit, "Villa Sofia-Cervello" Hospital, University of Palermo, Palermo, Italy.
Dig Dis. 2019;37(6):451-457. doi: 10.1159/000500116. Epub 2019 May 10.
Inflammatory bowel disease (IBD) and psoriasis (PS) are associated conditions. The reason for this association lies in the sharing of predisposition genes and common immunological mechanisms.
This review will focus on the interplay between IBD and PS, with details on prevalence and phenotype of PS in IBD, genetics, pathogenetic pathways, and therapy. Key Messages: Microbiome seems relevant in both conditions: a reduction of beneficial bacteria has been observed. IBD and PS have in common some comorbidities like cardiovascular disease, similar risk of cancer and psychiatric problems. Many biological therapies such as anti-tumour necrosis factor (TNF) and anti-interleukin 23 are effective in both conditions, underlining the common immunological mechanisms. Paradoxical PS has been mainly observed after anti-TNF therapies, but preliminary reports show that it can also occur with other biologics. Genetic predisposition to this phenomenon has been reported.
炎症性肠病(IBD)和银屑病(PS)是相关疾病。这种关联的原因在于易患基因和共同免疫机制的共享。
本文将重点介绍 IBD 和 PS 之间的相互作用,详细介绍 IBD 中 PS 的患病率和表型、遗传学、发病机制途径和治疗。
微生物组在这两种情况下似乎都很重要:已经观察到有益细菌的减少。IBD 和 PS 有一些共同的合并症,如心血管疾病、相似的癌症风险和精神问题。许多生物疗法,如抗肿瘤坏死因子(TNF)和抗白细胞介素 23 ,在这两种情况下都有效,这突出了共同的免疫机制。在抗 TNF 治疗后主要观察到矛盾性 PS,但初步报告显示,它也可能发生在其他生物制剂中。已经报道了这种现象的遗传易感性。